Groupes Coop rateurs en Oncologie (GCO)

The Groupes Coop rateurs en Oncologie (GCO) known in English as the Oncology Cooperative Groups are a network of Frenchbased clinical research organisations that design, conduct and monitor multicentre therapeutic trials for cancer patients. Founded in 1995, the GCO unites university hospitals, comprehensive cancer centres and peripheral oncology units, allowing them to pool expertise, patient populations and resources to answer the most pressing questions in cancer care.

Mission and Core Objectives

• Advance translational oncology: bridge laboratory discoveries with bedside applications through phase IIII clinical trials.
• Standardise treatment protocols: develop evidencebased guidelines that can be adopted across French and European practice.
• Promote equitable access: ensure that patients regardless of geography or centre size can participate in innovative studies.
• Facilitate data sharing: create secure, interoperable databases that support metaanalyses and realworld evidence generation.
• Train the next generation: provide mentorship and formal training for young oncologists, biostatisticians and research nurses.

Organisational Structure

The GCO is governed by a steering committee composed of senior oncologists, epidemiologists, patientrepresentatives and healthpolicy experts. Below the steering committee are specialised subgroups, each focused on a tumour type or methodological field:

1. Breast Cancer Group (BCG) trials on HER2targeted therapy, CDK4/6 inhibitors and neoadjuvant strategies.
2. Haematology Group (HG) studies of CART cells, novel alkylating agents and maintenance regimens.
3. GIOncology Group (GIO) investigations into immunotherapy for colorectal, gastric and pancreatic cancers.
4. Radiation Oncology Working Party (ROWP) integration of stereotactic body radiotherapy with systemic agents.
5. Biomarkers & Translational Research Unit (BTRU) collection of tissue, blood and imaging data for molecular profiling.

Key Achievements (19952024)

Over nearly three decades, the GCO has contributed to more than 150 published trials, many of which have changed the standard of care in France and beyond.

Research Workflow

Every GCO project follows a transparent, stepbystep workflow designed to protect patient safety and ensure scientific rigour:

1. Idea generation clinicians identify unmet needs; basic scientists propose mechanistic hypotheses.
2. Protocol development detailed statistical plan, eligibility criteria and safety monitoring are drafted.
3. Ethics & regulatory approval submission to the French National Ethics Committee (CPP) and ANSM.
4. Site activation participating centres receive training, sourcedocuments and eCRF access.
5. Patient enrollment informed consent, baseline assessments and randomisation.
6. Data collection & monitoring realtime electronic capture, onsite monitoring visits, and central data cleaning.
7. Interim analysis independent Data Safety Monitoring Board evaluates efficacy and toxicity.
8. Final analysis & publication results are peerreviewed, presented at conferences and deposited in the GCO trial registry.

Collaboration with International Networks

The GCO maintains formal partnerships with European and global consortia, including:

• European Society for Medical Oncology (ESMO) Clinical Trial Network
• U.S. National Cancer Institute (NCI) Cancer Trials Support Unit
• American Society of Clinical Oncology (ASCO) Clinical Trial Initiative

These collaborations enable joint sponsor agreements, pooled funding, and the sharing of patient cohorts for rare tumour subtypes.

Patient Involvement

Since 2010, the GCO has embedded patient advocates in every subgroup. Their responsibilities include:

• Reviewing patientinformation sheets for clarity and relevance.
• Participating in protocol design to ensure realistic eligibility criteria.
• Providing feedback on qualityoflife endpoints.
• Assisting in dissemination of results through lay summaries and community workshops.

Funding and Sustainability

The GCOs financial model is a blend of public and private sources:

• National Health Insurance (CNAM) core funding for infrastructure and staff salaries.
• Research grants competitive calls from the French National Cancer Institute (INCA) and European Horizon Europe programme.
• Industry partnerships collaborative agreements with pharmaceutical companies for drug supply and trial sponsorship, governed by strict conflictofinterest policies.

Annual budgets average 45million, allowing for the operation of a central datamanagement centre, a biobank, and a dedicated pharmacovigilance unit.

Future Directions (20252035)

Looking ahead, the GCO has identified three strategic priorities:

1. Precision Oncology Platform integrate nextgeneration sequencing, circulatingtumour DNA, and artificialintelligencedriven decision support into trial enrolment.
2. Adaptive Trial Designs implement Bayesian and platform trial frameworks to evaluate multiple therapies simultaneously, reducing time to market.
3. RealWorld Evidence (RWE) Hub link trial data with national cancer registries and electronic health records to monitor longterm outcomes and healtheconomic impact.

How to Get Involved

Clinicians, researchers and patient advocates interested in joining the GCO can:

• Visit the official portal gco-oncologie.fr and register for the newsletter.
• Apply to become a trial site by submitting a centrecapability questionnaire.
• Participate in the annual GCO Symposium, where investigators present ongoing studies and network.
• Contribute to the biobank by providing consented tissue samples for translational projects.

All data and trial identifiers are illustrative. For uptodate information, refer to the GCO website and peerreviewed publications.